$16.31
Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
Beta Bionics First in Automated Insulin Delivery to Publish Near Real-Time Real-World Data on a Public Website
Overview
52-week range
$8.80
$33
31% of range
Avg surprise (last 2)
+10.8%
Avg reaction (last 1)
-2.8%
0% positive
Latest IV / EM
106%
EM ±24.2% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $-0.49 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $-0.33 | — | — | — | — | financials |
| Tue Jul 29, 2025 | Jun/2025 | $-0.39 | $-0.51 | +23.5% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.52 | $-0.51 | -2.0% | — | -2.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.46 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.37 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-2.07 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Jul 29, 2026 | Jun/2026 | AMC | -$0.62 | -$0.39 | -59.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28M | — | $27M | $23M | $18M | — | $17M | $15M |
| Cost of revenue | $11M | — | $12M | $11M | $9M | — | $8M | $7M |
| Gross profit | $16M | — | $15M | $13M | $9M | — | $9M | $8M |
| Operating income | $-24M | — | $-17M | $-20M | $-19M | — | $-11M | $-12M |
| Net income | $-22M | — | $-14M | $-17M | $-29M | — | $-10M | $-14M |
| EPS (diluted) | $-0.49 | — | $-0.33 | $-0.39 | $-0.93 | — | $-1.46 | $-2.37 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30M | $32M | $38M | $35M | $42M | $30M | $17M | $13M |
| Inventory | $24M | $22M | $20M | $17M | $16M | $13M | — | — |
| Total current assets | $248M | $268M | $270M | $286M | $262M | $133M | — | — |
| Total assets | $304M | $329M | $330M | $330M | $338M | $150M | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $33M | $41M | $35M | $28M | $24M | $74M | — | — |
| Total equity | $271M | $288M | $295M | $302M | $314M | $-245M | $-229M | $-221M |